Skip to content

US · NDRA · MEDICAL - DIAGNOSTICS & RESEARCH

ENDRA Life Sciences Inc. (NDRA) intrinsic value and stock valuation

$3.58as of 2026-11-21 · Mkt cap 3.42M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ENDRA Life Sciences Inc. DCF and intrinsic value

InvestorsCraft values NDRA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NDRA’s statements →

ENDRA Life Sciences Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Ann Arbor, MI 48105-1570 endrainc.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$0.00
20142025
Net income
-$-7.03M
20142025
Free cash flow
-$-5.2M
20142025
Total equity
$2.26M-20.6% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-5.76M-$-10.82M-$-10.52M-$-13.16M-$-11.5M
Net income-$-7.03M-$-11.51M-$-10.06M-$-13.18M-$-11.23M
EPSd-$-8.9M-$-10.28M-$-5.88M-$-6.83M-$-5.48M
Operating cash flow-$-5.18M-$-7.4M-$-9.55M-$-12.77M-$-11.12M
Capital expenditure-$-20K-$-20K-$-30K-$-200K-$-40K
Free cash flow-$-5.2M-$-7.42M-$-9.58M-$-12.97M-$-11.17M
Total assets$3.85M$4.45M$6.75M$9.27M$12.9M
Total debt$490K$750K$390K$550K$800K
Net debt-$-270K-$-2.48M-$-2.44M-$-4.34M-$-8.67M
Total equity$2.26M$2.56M$5.66M$7.2M$10.8M
Cash and short-term investments$760K$3.23M$2.83M$4.89M$9.46M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$1.85M$3.19M$5M$6.55M$5.48M
Selling, general and administrative expenses$3.91M$7.63M$5.52M$6.6M$6.02M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$5.76M$10.8M$10.5M$13.2M$11.5M
Cost and expenses$5.76M$10.8M$10.5M$13.2M$11.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$20K$0.00
Depreciation and amortization$160K$210K$280K$230K$220K
Ebitda-$-6.87M-$-11.3M-$-9.78M-$-12.92M-$-11.01M
Operating income-$-5.76M-$-10.82M-$-10.52M-$-13.16M-$-11.5M
Total other income/expenses, net-$-1.26M-$-690K$460K-$-20K$270K
Income before tax-$-7.03M-$-11.51M-$-10.06M-$-13.18M-$-11.23M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-7.03M-$-11.51M-$-10.06M-$-13.18M-$-11.23M
Weighted average shares outstanding$790K$1.12M$1.71M$1.93M$2.05M
Weighted average diluted shares outstanding$790K$1.12M$1.71M$1.93M$2.05M
Balance sheet
20252024202320222021
Cash and short-term investments$760K$3.23M$2.83M$4.89M$9.46M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$2.64M$1.28M
Total current assets$970K$3.43M$3.03M$8.53M$12.1M
Property, plant and equipment, net$500K$650K$470K$740K$770K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.89M$1.02M$3.72M$750K$780K
Total assets$3.85M$4.45M$6.75M$9.27M$12.9M
Accounts payable$380K$270K$360K$610K$790K
Short-term debt$130K$270K$200K$180K$250K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$750K$610K$900K$1.7M$1.54M
Long-term debt$360K$490K$190K$370K$550K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$840K$1.29M$190K$370K$550K
Capital lease obligations$490K$580K$370K$520K$650K
Total liabilities$1.59M$1.89M$1.1M$2.07M$2.09M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-110.47M-$-103.44M-$-91.93M-$-81.87M-$-68.69M
Accumulated other comprehensive income (loss)$0.00$0.00$10K$10K$10K
Total equity$2.26M$2.56M$5.66M$7.2M$10.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$490K$750K$390K$550K$800K
Net debt-$-270K-$-2.48M-$-2.44M-$-4.34M-$-8.67M
Cash flow statement
20252024202320222021
Net income-$-7.03M-$-11.51M-$-10.06M-$-13.18M-$-11.23M
Depreciation and amortization$160K$210K$280K$230K$220K
Stock-based compensation$330K$570K$1M$1.2M$1.44M
Change in working capital$20K$130K-$-920K-$-1.03M-$-1.26M
Accounts receivable$0.00$0.00$0.00$0.00-$-490K
Inventory$0.00$240K$140K-$-1.36M-$-690K
Accounts payable$110K-$-200K-$-820K$110K$490K
Net cash provided by operating activities-$-5.18M-$-7.4M-$-9.55M-$-12.77M-$-11.12M
Investments in property, plant and equipment-$-20K-$-20K-$-30K-$-200K-$-40K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-3.02M-$-10K-$-20K-$-200K-$-40K
Common stock issued$5.73M$7.84M$6.48M$8.4M$10.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-10K-$0.00-$-10K-$-120K
Net cash used for financing activities$5.73M$7.81M$7.52M$8.4M$13.4M
Net change in cash-$-2.47M$400K-$-2.06M-$-4.57M$2.23M
Cash at end of period$760K$3.23M$2.83M$4.89M$9.46M
Operating cash flow-$-5.18M-$-7.4M-$-9.55M-$-12.77M-$-11.12M
Capital expenditure-$-20K-$-20K-$-30K-$-200K-$-40K
Free cash flow-$-5.2M-$-7.42M-$-9.58M-$-12.97M-$-11.17M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ENDRA Life Sciences Inc.

        ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.

        CEO
        Alexander Y. Tokman
        Employees
        11
        Beta
        -0.07

        Explore

        Frequently asked questions

        What is the intrinsic value of ENDRA Life Sciences Inc. (NDRA)?

        InvestorsCraft does not currently publish an intrinsic value for NDRA. How the IC value is calculated.

        Is NDRA undervalued?

        InvestorsCraft does not publish an undervaluation signal for NDRA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.